Vivtex Analysis
What is Vivtex?
Vivtex uses a proprietary GI-ORIS™ platform to screen intact gastrointestinal tract tissue for oral drug delivery. The technology enables fully automated robotic testing of drug absorption and toxicity in functional human tissue. The company develops new oral therapeutics to replace injectable treatments, aiming to improve patient adherence and therapy efficacy.
Location
Boston, United States
Employees
11-50
Founded
2018
Product Features & Capabilities
- GI-ORIS™ robotic screening platform for intact GI tissue
- Oral drug delivery system development
- Drug toxicity mitigation testing
- Spatial and temporal drug delivery evaluation
Use Cases
Screen oral drug candidates for absorption in human GI tissue; Test drug toxicity in functional intact tissue; Identify lead formulations with high GI absorption; Develop new oral therapeutics to replace injectable drugs; Evaluate drug delivery timing and location in GI tract
Other Considerations
Invented by MIT Langer Lab; Co-founded by Robert Langer and Dr. Giovanni Traverso; Featured in Nature and StatNews; Partnerships with NIH and Scientific American; Preclinical stage with multiple drug development programs
See something that needs updating? Suggest edits to this profile.